Home CyclinD1 is a new target gene of tumor suppressor miR-520e in breast cancer
Article Open Access

CyclinD1 is a new target gene of tumor suppressor miR-520e in breast cancer

  • Quan Liang EMAIL logo , Qingjuan Yao and GuoYing Hu
Published/Copyright: December 4, 2019
Download Article (PDF)
Open Medicine
From the journal Open Medicine Volume 14 Issue 1

Abstract

Objective

To investigate the involvement of miR-520e in the modulation of cancer-promoting cyclinD1 in breast cancer.

Methods

A reverse transcription-polymerase chain reaction (RT-PCR) was applied to test the regulation of miR-520e on cyclinD1. The binding of miR-520e to 3’-untranslated region (3’UTR) of cyclinD1 mRNA was predicted by an online bioinformatics website. The effect of miR-520e on the luciferase reporters with binding sites of miR-520e and 3’UTR of cyclinD1 mRNA was revealed using a luciferase reporter gene assay. The correlation between miR-520e and cyclinD1 in clinical breast cancer samples was detected through quantitative real-time PCR.

Results

The expression of cyclinD1 was gradually reduced as the dose of miR-520e increased. Anti-miR-520e obviously induced cyclinD1 in breast cancer cells. After anti-miR-520e was introduced into the cells, the inhibition of cyclinD1 expression mediated by miR-520e was reversed. The binding of miR-520e with cyclinD1 was revealed via bioinformatics. Under the treatment of dose-increasing miR-520e or anti-miR-520e, the luciferase activities of cyclinD1 3’UTR vector were lower or higher by degrees. However, the activity of the mutant vector was not affected at all. Finally, in clinical breast cancer tissues the negative correlation of miR-520e with cyclinD1 was revealed.

Conclusion

In conclusion, cyclinD1 is a new target of miR-520e in breast cancer.

Keywords: CyclinD1; miR-520e; Breast cancer

1 Introduction

MicroRNAs can regulate the expression of genes through making mRNA degradation or inhibit translation. During the development of cancer, microRNAs can function as cancer promoters or cancer suppressors. A report has revealed that miR-520e makes breast cancer cells sensitive to complement attacks, resulting in the suppression of breast cancer [1]. Some microarray data shows that lots of microRNAs including miR-520e might be related to the occurrence and development of breast cancer [2]. MiR-520e can have a great part in the modulation of progression of breast cancer [3]. In other studies, miR-520e is found to inhibit hepatocarcinogenesis and interact with NIK in liver cancer [4, 5]. MiR-520e-targeting EphA2 involves the MAPK pathway and then functions in HBV replication or liver cancer growth [6]. Some researchers have made progress in delivering miR-520e for lung cancer therapy [7]. Some analyses of microarray and microRNA profiling reveal an association of miR-520e with JAK1 in lung cancer[8]. MiR-520e can repress cell proliferation, migration and invasion through interacting with Zbtb7a in non-small cell lung cancer [9]. In response to TGF-β, SMAD-activated miR-520e is able to target TGFBR2, resulting in the suppression of NSCLC metastasis [10]. MiR-520e with some other microRNAs is involved in the development of lynch syndrome [11]. In glioma, miR-520e can target FGF19 to inhibit the Wnt/β-catenin pathway for destroying cell growth and invasion [12]. However, the role of miR-520e and its new target still need investigating.

Serving as an important cell cycle driver, the cyclinD1 protein is encoded by the CCND1 gene and it is a prognostic and predictive factor in cancers. Previous studies reported that cyclinD1 could serve as a prognostic predictor in esophageal squamous cell carcinomas [13, 14]. A high expression of cyclinD1 is closely associated with cell proliferation of pancreatic cancer through analyzing human clinical tissues [15]. The survival of a cervical cancer patient is shorter when their cyclinD1 and survivin are overexpressed [16]. Elevated cyclinD1 can be downregulated by metastasis associated-1 knockdown to inhibit the cell proliferation and invasion of breast cancer [17]. CyclinD1 can function as a target of aspirin in resisting tamoxifen resistance in breast cancer [18]. BATF3/AP-1/cyclinD1signaling is a target of miR-760 in depressing the growth of colorectal cancer [19]. In glioblastoma, cyclinD1 can be targeted by miR-16 [20]. It remains unclear whether miR-520e could post-transcriptionally modulate cyclinD1 in breast cancer.

In our study, we tried to explore the function of tumor suppressive miR-520e in the modulation of cyclinD1 expression in breast cancer. Our finding shows that miR-520e is able to control the expression of cyclinD1 in breast cancer cells. For the regulatory mechanism investigation, we reveal that miR-520e can directly bind to the 3’UTR region of cyclinD1 to degrade its mRNA. In human clinical breast cancer tissues, we observed a negative correlation of miR-520e with cyclinD1. Our finding will emphasize the potential utilization of miR-520e and cyclinD1 in the treatment of breast cancer in the future.

2 Methods

2.1 Cell culture

Breast cancer cell line MCF-7 was grown in RPMI Medium 1640 (Gibco, USA) with 10% fetal bovine serum (Gibco) and maintained via a 5% CO2 incubator at 37°C.

2.2 MicroRNA mimic transfection

Lipofectamine 2000 (Invitrogen, USA) was used to transfect miR-520e and its antagonist, anti-miR-520e into MCF-7 cells. MiR-520e, anti-miR-520e and their control were bought from RiboBio (Guangzhou, China).

2.3 Patient tissues

Twenty cases of breast cancer tissues and paired noncancerous tissues were obtained from breast cancer patients with post-surgical written consents at the General Hospital of Tianjin Medical University (Tianjin, China) (Supporting Table S1). The Research Ethics Board has approved the study protocol used here.

2.4 RNA extraction, reverse transcription-polymerase chain reaction (RT-PCR) and quantitative real-time PCR

The total RNA of breast cancer MCF-7 cells and clinical breast cancer samples was obtained by utilizing the TRIzol Reagent (Invitrogen, USA). For the detection of the cyclinD1 mRNA level, reverse transcription was performed by GoScriptTM Reverse Transcriptase (Promega, USA) and GAPDH was used as a loading control. Quantitative real-time PCR was performed using the QuantiNova SYBR Green PCR kit (Qiagen, Valencia, CA, USA). The relative cyclinD1 mRNA levels were analyzed by normalizing the threshold cycle (Ct) value to that of the internal loading control, GAPDH. For miR-520e, its level was measured using a TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher, Carlsbad, CA, USA) and TaqMan gene expression master mix (Thermo Fisher, Carlsbad, CA, USA) according to the manufacturer’s protocol. The level of miR-520e was analyzed by normalizing the threshold cycle (Ct) value to that of the internal loading control, U6 snRNA. In Figure 1 and 2, one-point detection of cyclinD1 was per

Figure 1 MiR-520e restrains the expression of cyclinD1 in breast cancer MCF-7 cells. (A, B) After miR-520e or anti-miR-520e was induced into MCF-7 cells, the level of cyclinD1 was determined by using RT-PCR assay of one-point detection in electrophoresis results and quantitative real-time PCR from a minimum of three different repeats for each sample. Meanwhile, the level of miR-520e in the cells transfected with miR-520e and anti-miR-520e was evaluated by quantitative real-time PCR. Statistical quantification from at least three independent experiments is included. *P <0.05; **P < 0.01; ***P < 0.001; Student’s t test.
Figure 1

MiR-520e restrains the expression of cyclinD1 in breast cancer MCF-7 cells. (A, B) After miR-520e or anti-miR-520e was induced into MCF-7 cells, the level of cyclinD1 was determined by using RT-PCR assay of one-point detection in electrophoresis results and quantitative real-time PCR from a minimum of three different repeats for each sample. Meanwhile, the level of miR-520e in the cells transfected with miR-520e and anti-miR-520e was evaluated by quantitative real-time PCR. Statistical quantification from at least three independent experiments is included. *P <0.05; **P < 0.01; ***P < 0.001; Student’s t test.

Figure 2 Anti-miR-520e reverses the inhibition of cyclinD1 induced by miR-520e. The expression of cyclinD1 at the mRNA level was tested by using RT-PCR assay of one-point detection in electrophoresis results and quantitative real-time PCR from a minimum of three different repeats for each sample. Meanwhile, the level of miR-520e in the cells transfected with miR-520e and anti-miR-520e was evaluated by quantitative real-time PCR when MCF-7 cells were treated with negative control mimics, miR-520e and/or anti-miR-520e. Statistical quantification from at least three independent experiments is included. *P <0.05; **P < 0.01; ***P < 0.001; Student’s t test.
Figure 2

Anti-miR-520e reverses the inhibition of cyclinD1 induced by miR-520e. The expression of cyclinD1 at the mRNA level was tested by using RT-PCR assay of one-point detection in electrophoresis results and quantitative real-time PCR from a minimum of three different repeats for each sample. Meanwhile, the level of miR-520e in the cells transfected with miR-520e and anti-miR-520e was evaluated by quantitative real-time PCR when MCF-7 cells were treated with negative control mimics, miR-520e and/or anti-miR-520e. Statistical quantification from at least three independent experiments is included. *P <0.05; **P < 0.01; ***P < 0.001; Student’s t test.

Table 1

Clinical characteristics of breast cancer samples

No. Sex Age Pathology diagnosis
1 F 45 Breast cancer
2 F 38 Breast cancer
3 F 33 Breast cancer
4 F 47 Breast cancer
5 F 51 Breast cancer
6 F 39 Breast cancer
7 F 44 Breast cancer
8 F 30 Breast cancer
9 F 52 Breast cancer
10 F 59 Breast cancer
11 F 46 Breast cancer
12 F 48 Breast cancer
13 F 37 Breast cancer
14 F 52 Breast cancer
15 F 54 Breast cancer
16 F 49 Breast cancer
17 F 56 Breast cancer
18 F 55 Breast cancer
19 F 34 Breast cancer
20 F 43 Breast cancer

formed by RT-PCR assay and then run for electrophoresis. Also, the level of miR-520e and cyclinD1 was tested from a minimum of three different repeats for each sample through a quantitative real-time PCR assay after miR-520e or anti-miR-520e was transfected into breast cancer cells. In Figure 4, the level of miR-520e and cyclinD1 in clinical breast cancer tissues was tested from a minimum of three different repeats for each sample through a quantitative real-time PCR assay.

2.5 Constructs

pGL3-control vectors with a wild type or a mutant binding site between miR-520e and cyclinD1 3’UTR were constructed. The primers were used as follows: wt forward, 5’- GCTCTAGACCATTCCATTTCCAAGCACTTT-3’, reverse, 5’-GGGGGCCGGCC GGAAAGGAACTTATCATCCT-3’; mut forward, 5’- GCTCTAGAGGATAGCATTTCCTTCGT-GAAT-3’, reverse, 5’-GGGGGCCGGCC GGAAAGGAACTTAT-CATCCT-3’).

2.6 Luciferase reporter analysis

MCF-7 cells were seeded on 24-well plates. Luciferase reporter vectors (wt or mut) with microRNA mimics (or control) were transfected with Lipofectamine 2000 (Invitrogen). Firefly luciferase activities were normalized by Renilla luciferase activities. The Dual-Luciferase® Reporter Assay System (Promega, USA) was applied for testing luciferase activity.

2.7 Statistical analysis

A student’s t-test was used to measure the statistical significance between the two groups. A P value less than 0.05 was thought statistically significant. The data are presented as mean ± SD, and all experiments were performed independently a minimum of three times. The correlation between miR-520e and cyclinD1 expression in human clinical breast cancer tissues was evaluated by Pearson’s correlation coefficient.

3 Results

3.1 MiR-520e restrains the expression of cyclinD1 in breast cancer MCF-7 cells

At first, we were wondering whether tumor suppressor miR-520e affected oncogenic cyclinD1 expression in breast cancer MCF-7 cells. We transiently transfected miR-520e mimics obtained from RiboBio (Guangzhou, China) into MCF-7 cells. The data revealed that, compared with the negative control (NC) group, the level of cyclinD1 had obviously decreased under the treatment of the elevated dose of miR-520e in the cells. These results were obtained from a RT-PCR assay of one-point detection in electrophoresis results and quantitative real-time PCR from three different repeat at least for each sample (Figure. 1A). In addition, we found that the inhibitor of miR-520e, anti-miR-520e could induce the expression of cyclinD1 in the cells. These results were obtained from a RT-PCR assay of one-point detection in electrophoresis results and quantitative real-time PCR from three different repeat at least for each sample (Figure. 1B). Meanwhile, the level of miR-520e in the cells transfected with miR-520e and anti-miR-520e was evaluated by quantitative real-time PCR (Figure 1A and 1B). In future experiments, we want to evaluate the effect of anti-miR-520e on miR-520e and cyclinD1 in breast cancer cells. Our results showed that miR-520e inhibited the level of cyclinD1 and then anti-miR-520e enhanced the expression of cyclinD1. Furthermore, the reintroduction of miR-520e in anti-miR-520e-treated cells could destroy the augmentation of cyclinD1 by anti-miR-520e in MCF-7 cells by using an RT-PCR assay of one-point detection in electrophoresis results and quantitative real-time PCR from a minimum of three different repeats for each sample (Figure. 2). At the same time, the overexpression or inhibition of miR-520e in the cells was confirmed by quantitative real-time PCR (Figure 2). Our finding implies that the tumor suppressor miR-520e can control the expression of cyclinD1 in breast cancer cells.

3.2 MiR-520e binds to the 3'UTR of cyclinD1 mRNA to reduce its level

To investigate how miR-520e regulates cyclinD1 in breast cancer cells, we searched for the binding sites between miR-520e and cyclinD1 through online software (http://www.targetscan.org) The binding site of miR-520e exists within the 3’ untranslated region (3’UTR) of cyclinD1 mRNA (Figure 3A). We next constructed the luciferase reporter vectors containing a wild-type or a mutant binding site of miR-520e with the 3’UTR of cyclinD1 mRNA (pGL3-cyclinD1-wt or pGL3-cyclinD1-mut) (Figure. 3B). Taking a step further, we examined whether miR-520e could weaken the luciferase activities of pGL3-cyclinD1-wt or pGL3-cyclinD1-mut. We observed that under treatment with an increased concentration of miR-520e, the luciferase activities of pGL3-cyclinD1-wt sharply decreased. When pGL3-cyclinD1-mut was introduced into the cells, miR-520e failed to affect the luciferase activities (Figure. 3C). However, anti-miR-520e could induce the luciferase

Figure 3 MiR-520e binds to the 3'UTR of cyclinD1 mRNA to reduce its level. (a) (A, B) The binding between miR-520e and the 3¢UTR of cyclinD1 mRNA is presented. The luciferase vector containing wild type and mutant binding sites within the 3¢UTR of cyclinD1 (wt or mut) with miR-520e is constructed. (C) The regulation of miR-520e on the luciferase activity of pGL3-cyclinD1-wt or pGL3-cyclinD1-mut was revealed through luciferase reporter assay in breast cancer MCF-7 cells. (D) The regulation of anti-miR-520e on the luciferase activity of pGL3-cyclinD1-wt or pGL3-cyclinD1-mut was revealed through luciferase reporter assay in breast cancer MCF-7 cells. NS, not significant; **P < 0.01; ***P < 0.001; Student’s t test.
Figure 3

MiR-520e binds to the 3'UTR of cyclinD1 mRNA to reduce its level. (a) (A, B) The binding between miR-520e and the 3¢UTR of cyclinD1 mRNA is presented. The luciferase vector containing wild type and mutant binding sites within the 3¢UTR of cyclinD1 (wt or mut) with miR-520e is constructed. (C) The regulation of miR-520e on the luciferase activity of pGL3-cyclinD1-wt or pGL3-cyclinD1-mut was revealed through luciferase reporter assay in breast cancer MCF-7 cells. (D) The regulation of anti-miR-520e on the luciferase activity of pGL3-cyclinD1-wt or pGL3-cyclinD1-mut was revealed through luciferase reporter assay in breast cancer MCF-7 cells. NS, not significant; **P < 0.01; ***P < 0.001; Student’s t test.

Figure 4 In human clinical breast cancer tissues, miR-520e is positively correlated with cyclinD1. The correlation of miR-520e and cyclinD1 was analyzed in clinical breast cancer tissues (Pearson′s correlation coefficient, R2=0.6092).
Figure 4

In human clinical breast cancer tissues, miR-520e is positively correlated with cyclinD1. The correlation of miR-520e and cyclinD1 was analyzed in clinical breast cancer tissues (Pearson′s correlation coefficient, R2=0.6092).

activities of pGL3-cyclinD1-wt. But it lost the control of pGL3-cyclinD1-mut (Figure. 3D). So, all our data indicate that cyclinD1 is a novel target gene of miR-520e in breast cancer.

3.3 In human clinical breast cancer tissues, miR-520e positively correlates with cyclinD1

CyclinD1 is overexpressed and implicated in the development of many types of cancers [14, 15, 16, 17, 18]. Researchers have presented evidence that miR-520e can play an inhibitory role during the progression of some cancers [1, 4, 5, 9, 10]. We want to know the correlation between miR-520e and its target gene, cyclinD1 in clinical breast cancer tissues. Twenty cases of human clinical breast cancer samples were utilized. Through a quantitative real time-PCR assay from a minimum of three different repeats for each sample, we found that in cyclinD1-upregulated breast cancer tissues the level of miR-520e was decreased and then in cyclinD1-downregulated breast cancer tissues miR-520e was elevated. Moreover, our data demonstrated that there was a negative correlation between the expression of cyclinD1 and the level of miR-520e in clinical breast cancer samples (Pearson′ correlation coefficient R2=0.6092, p < 0.01) (Figure. 4). Altogether, our finding presents that in clinical breast cancer samples, low miR-339 correlates with high cyclinD1.

4 Discussion

Among women, breast cancer always remains the most common cause of cancer mortality all around the world [21]. As one type of small non-coding RNA, microRNAs can directly interact with their target genes to promote the degradation of mRNA or the inhibition of translation, which may serve as a cancer promoter or cancer suppressor in different types of cancers including breast cancer. MiR-520e can suppress breast cancer through making breast cancer cells sensitive to complement attacks [1]. Some microarray data shows the correlation of miR-520e with the occurrence and development of breast cancer[2]. As an important cell cycle driver, cyclinD1 encoded by CCND1 is a prognostic and predictive factor in cancers. Elevated cyclinD1 can be downregulated by metastasis associated-1 knockdown to inhibit the cell proliferation and invasion of breast cancer [17]. CyclinD1 can function as a target of aspirin in resisting tamoxifen resistance in breast cancer [18]. However, the role of miR-520e in the modulation of cyclinD1 still remains unclear.

In our investigation, we firstly wanted to know whether tumor suppressive miR-520e can function in the regulation of oncogenic cyclinD1 in breast cancer. We synthetized miR-520e mimics and then transduced them into breast cancer cells. We observed that an elevated concentration of miR-520e could dramatically decrease the level of cyclinD1 in breast cancer MCF-7 cells. Meanwhile, the antagonist of miR-520e, anti-miR-520e induced the expression of cyclinD1. To further confirm the regulation of miR-520e on the expression of cyclinD1, we introduced miR-520e into the cells after its antagonist was transfected. As expected, miR-520e weakened the upregulation of cyclinD1 mediated by anti-miR-520e in the cells through quantitative real time-PCR analysis. To clarify how miR-520e modulates the expression of cyclinD1 at the post-transcription level, we used online software to predict the binding sites between miR-520e and cyclinD1 mRNA. The binding site of miR-520e is within the 3’UTR of cyclinD1 mRNA and we cloned the luciferase reporter vectors containing wild-type or mutant binding sites between miR-520e and cyclinD1 mRNA 3’UTR. We observed that miR-520e or anti-miR-520e obviously inhibited or induced the luciferase activities of a wild-type reporter vector and lost control over the mutant reporter vector. In human clinical breast cancer tissues, we analyzed the correlation of miR-520e and cyclinD1. The data showed a negative correlation between the level of miR-520e and the expression of cyclinD1 in breast cancer tissues. So, our finding proves that miR-520e can regulate the expression of cyclinD1 at the level of post-transcription in breast cancer.

In conclusion, we firstly report that oncogenic cyclinD1 is a novel target gene of tumor suppressor miR-520e in breast cancer. MiR-520e is capable of directly binding to the 3’UTR of cyclinD1 mRNA to promote the degradation of cyclinD1 mRNA, leading to the inhibition of cyclinD1 in breast cancer. Therapeutically, our finding provides new evidence and support for the utilization of miR-520e and cyclinD1 in breast cancer treatment.

Disclosure

No authors report any conflict of interest.

References

[1] Cui W, Zhang Y, Hu N, Shan C, Zhang S, Zhang W, et al. miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3’UTR of CD46. Cancer biology & therapy. 2010; 10: 232-24110.4161/cbt.10.3.12277Search in Google Scholar PubMed

[2] Chen D, Yang H. Integrated analysis of differentially expressed genes in breast cancer pathogenesis. Oncology letters. 2015; 9: 2560-256610.3892/ol.2015.3147Search in Google Scholar PubMed PubMed Central

[3] Yi M, Li M, Long X, Ye J, Cui J, Wei W, et al. miR-520e regulates cell proliferation, apoptosis and migration in breast cancer. Oncology letters. 2016; 12: 3543-354810.3892/ol.2016.5085Search in Google Scholar PubMed PubMed Central

[4] Zhang S, Shan C, Kong G, Du Y, Ye L, Zhang X. MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-kappaB-inducing kinase (NIK). Oncogene. 2012; 31: 3607-362010.1038/onc.2011.523Search in Google Scholar PubMed

[5] Li BA. A novel tumor suppressor miRNA miR-520e contributes to suppression of hepatoma. Acta pharmacologica Sinica. 2012; 33: 3-410.1038/aps.2011.198Search in Google Scholar PubMed PubMed Central

[6] Tian JH, Liu WD, Zhang ZY, Tang LH, Li D, Tian ZJ, et al. Influence of miR-520e-mediated MAPK signalling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2. Journal of Viral Hepatitis. 2018 Dec 06;doi:10.1111/jvh.13048. [Epub ahead of print]10.1111/jvh.13048Search in Google Scholar PubMed

[7] Ma D, Lu H, Qu Y, Fu W, Ma Z. Developing an effective therapeutic by delivery of synthetic microRNA-520e in lung cancer treatment. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2015; 69:249-25410.1016/j.biopha.2014.12.009Search in Google Scholar PubMed

[8] Wang F, Meng F, Wang L, Wong SC, Cho WC, Chan LW. Associations of mRNA:microRNA for the Shared Downstream Molecules of EGFR and Alternative Tyrosine Kinase Receptors in Non-small Cell Lung Cancer. Frontiers in genetics. 2016; 7: 17310.3389/fgene.2016.00173Search in Google Scholar PubMed PubMed Central

[9] Zhijun Z, Jingkang H. MicroRNA-520e suppresses non-small-cell lung cancer cell growth by targeting Zbtb7a-mediated Wnt signaling pathway. Biochemical and biophysical research communications. 2017; 486: 49-5610.1016/j.bbrc.2017.02.121Search in Google Scholar PubMed

[10] Kucuksayan H, Akgun S, Ozes ON, Alikanoglu AS, Yildiz M, Dal E, et al. TGF-β-SMAD-miR-520e axis regulates NSCLC metastasis through a TGFBR2-mediated negative feedback loop. Carcinogenesis 2018 Nov 22;pii:5197069. doi:10.1093/carcin/bgy166. [Epub ahead of print]10.1093/carcin/bgy166Search in Google Scholar PubMed

[11] Zhou C, Li J, Li J, Wan Y, Li T, Ma P, et al. Hsa-miR-137, hsa-miR-520e and hsa-miR-590-3p perform crucial roles in Lynch syndrome. Oncology letters. 2016; 12: 2011-201710.3892/ol.2016.4816Search in Google Scholar

[12] Zhang L, Cao Y, Jia D, Wei M. MicroRNA-520e restricts the proliferation and invasion of glioma cells through the downregulation of Wnt/beta-catenin signaling by targeting fibroblast growth factor 19. Biochemical and biophysical research communications. 2019: 511: 619-62510.1016/j.bbrc.2019.02.112Search in Google Scholar

[13] Itami A, Shimada Y, Watanabe G, Imamura M. Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology. 1999; 57: 311-31710.1159/000012067Search in Google Scholar

[14] Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases. Journal of the American College of Surgeons. 2001; 192: 708-71810.1016/S1072-7515(01)00840-7Search in Google Scholar

[15] Li YJ, Wei ZM, Meng YX, Ji XR. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World journal of gastroenterology: WJG. 2005; 11: 2117-212310.3748/wjg.v11.i14.2117Search in Google Scholar PubMed PubMed Central

[16] Lu S, Zhang B, Wang Z. Expression of survivin, cyclinD1, p21(WAF1), caspase-3 in cervical cancer and its relation with prognosis. Journal of Huazhong University of Science and Technology. Medical sciences. 2005; 25: 78-8110.1007/BF02831393Search in Google Scholar PubMed

[17] Jiang Q, Zhang H, Zhang P. ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro. Journal of experimental & clinical cancer research : CR. 2011; 30: 6010.1186/1756-9966-30-60Search in Google Scholar PubMed PubMed Central

[18] Cheng R, Liu YJ, Cui JW, Yang M, Liu XL, Li P, et al. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncotarget. 2017; 8: 30252-3026410.18632/oncotarget.16325Search in Google Scholar PubMed PubMed Central

[19] Cao L, Liu Y, Wang D, Huang L, Li F, Liu J, et al. MiR-760 suppresses human colorectal cancer growth by targeting BATF3/AP-1/cyclinD1 signaling. Journal of experimental & clinical cancer research : CR. 2018; 37: 8310.1186/s13046-018-0757-8Search in Google Scholar PubMed PubMed Central

[20] Tian R, Wang J, Yan H, Wu J, Xu Q, Zhan X, et al. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis. Oncogene. 2017; 36: 5861-587310.1038/onc.2017.182Search in Google Scholar PubMed PubMed Central

[21] Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nature reviews Cancer. 2007; 7: 659-67210.1038/nrc2193Search in Google Scholar PubMed

Received: 2019-06-17
Accepted: 2019-09-24
Published Online: 2019-12-04

© 2019 Quan Liang et al., published by De Gruyter

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Articles in the same Issue

  1. Research Article
  2. Prostate Cancer-Specific of DD3-driven oncolytic virus-harboring mK5 gene
  3. Case Report
  4. Pediatric acute paradoxical cerebral embolism with pulmonary embolism caused by extremely small patent foramen ovale
  5. Research Article
  6. Associations between ambient temperature and acute myocardial infarction
  7. Case Report
  8. Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
  9. Research Article
  10. METTL3 promotes the proliferation and mobility of gastric cancer cells
  11. The C677T polymorphism of the methylenetetrahydrofolate reductase gene and susceptibility to late-onset Alzheimer’s disease
  12. microRNA-1236-3p regulates DDP resistance in lung cancer cells
  13. Review Article
  14. The link between thyroid autoimmunity, depression and bipolar disorder
  15. Research Article
  16. Effects of miR-107 on the Chemo-drug sensitivity of breast cancer cells
  17. Analysis of pH dose-dependent growth of sulfate-reducing bacteria
  18. Review Article
  19. Musculoskeletal clinical and imaging manifestations in inflammatory bowel diseases
  20. Research Article
  21. Regional hyperthermia combined with chemotherapy in advanced gastric cancer
  22. Analysis of hormone receptor status in primary and recurrent breast cancer via data mining pathology reports
  23. Morphological and isokinetic strength differences: bilateral and ipsilateral variation by different sport activity
  24. The reliability of adjusting stepped care based on FeNO monitoring for patients with chronic persistent asthma
  25. Comparison of the clinical outcomes of two physiological ischemic training methods in patients with coronary heart disease
  26. Analysis of ticagrelor’s cardio-protective effects on patients with ST-segment elevation acute coronary syndrome accompanied with diabetes
  27. Computed tomography findings in patients with Samter’s Triad: an observational study
  28. Case Report
  29. A spinal subdural hematoma induced by guidewire-based lumbar drainage in a patient with ruptured intracranial aneurysms
  30. Research Article
  31. High expression B3GAT3 is related with poor prognosis of liver cancer
  32. Effects of light touch on balance in patients with stroke
  33. Oncoprotein LAMTOR5 activates GLUT1 via upregulating NF-κB in liver cancer
  34. Effects of budesonide combined with noninvasive ventilation on PCT, sTREM-1, chest lung compliance, humoral immune function and quality of life in patients with AECOPD complicated with type II respiratory failure
  35. Prognostic significance of lymph node ratio in ovarian cancer
  36. Case Report
  37. Brainstem anaesthesia after retrobulbar block
  38. Review Article
  39. Treating infertility: current affairs of cross-border reproductive care
  40. Research Article
  41. Serum inflammatory cytokines comparison in gastric cancer therapy
  42. Behavioural and psychological symptoms in neurocognitive disorders: Specific patterns in dementia subtypes
  43. MRI and bone scintigraphy for breast cancer bone metastase: a meta-analysis
  44. Comparative study of back propagation artificial neural networks and logistic regression model in predicting poor prognosis after acute ischemic stroke
  45. Analysis of the factors affecting the prognosis of glioma patients
  46. Compare fuhrman nuclear and chromophobe tumor grade on chromophobe RCC
  47. Case Report
  48. Signet ring B cell lymphoma: A potential diagnostic pitfall
  49. Research Article
  50. Subparaneural injection in popliteal sciatic nerve blocks evaluated by MRI
  51. Loneliness in the context of quality of life of nursing home residents
  52. Biological characteristics of cervical precancerous cell proliferation
  53. Effects of Rehabilitation in Bankart Lesion in Non-athletes: A report of three cases
  54. Management of complications of first instance of hepatic trauma in a liver surgery unit: Portal vein ligation as a conservative therapeutic strategy
  55. Matrix metalloproteinase 2 knockdown suppresses the proliferation of HepG2 and Huh7 cells and enhances the cisplatin effect
  56. Comparison of laparoscopy and open radical nephrectomy of renal cell cancer
  57. Case Report
  58. A severe complication of myocardial dysfunction post radiofrequency ablation treatment of huge hepatic hemangioma: a case report and literature review
  59. Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report
  60. Research Article
  61. Binge eating disorder and related features in bariatric surgery candidates
  62. Propofol versus 4-hydroxybutyric acid in pediatric cardiac catheterizations
  63. Nasointestinal tube in mechanical ventilation patients is more advantageous
  64. The change of endotracheal tube cuff pressure during laparoscopic surgery
  65. Correlation between iPTH levels on the first postoperative day after total thyroidectomy and permanent hypoparathyroidism: our experience
  66. Case Report
  67. Primary angiosarcoma of the kidney: case report and comprehensive literature review
  68. Research Article
  69. miR-107 enhances the sensitivity of breast cancer cells to paclitaxel
  70. Incidental findings in dental radiology are concerning for family doctors
  71. Suffering from cerebral small vessel disease with and without metabolic syndrome
  72. A meta-analysis of robot assisted laparoscopic radical prostatectomy versus laparoscopic radical prostatectomy
  73. Indications and outcomes of splenectomy for hematological disorders
  74. Expression of CENPE and its prognostic role in non-small cell lung cancer
  75. Barbed suture and gastrointestinal surgery. A retrospective analysis
  76. Using post transplant 1 week Tc-99m DTPA renal scan as another method for predicting renal graft failure
  77. The pseudogene PTTG3P promotes cell migration and invasion in esophageal squamous cell carcinoma
  78. Lymph node ratio versus TNM system as prognostic factor in colorectal cancer staging. A single Center experience
  79. Review Article
  80. Minimally invasive pilonidal sinus treatment: A narrative review
  81. Research Article
  82. Anatomical workspace study of Endonasal Endoscopic Transsphenoidal Approach
  83. Hounsfield Units on Lumbar Computed Tomography for Predicting Regional Bone Mineral Density
  84. Communication
  85. Aspirin, a potential GLUT1 inhibitor in a vascular endothelial cell line
  86. Research Article
  87. Osteopontin and fatty acid binding protein in ifosfamide-treated rats
  88. Familial polyposis coli: the management of desmoid tumor bleeding
  89. microRNA-27a-3p down-regulation inhibits malignant biological behaviors of ovarian cancer by targeting BTG1
  90. PYCR1 is associated with papillary renal cell carcinoma progression
  91. Prediction of recurrence-associated death from localized prostate cancer with a charlson comorbidity index–reinforced machine learning model
  92. Colorectal cancer in the elderly patient: the role of neo-adjuvant therapy
  93. Association between MTHFR genetic polymorphism and Parkinson’s disease susceptibility: a meta-analysis
  94. Metformin can alleviate the symptom of patient with diabetic nephropathy through reducing the serum level of Hcy and IL-33
  95. Case Report
  96. Severe craniofacial trauma after multiple pistol shots
  97. Research Article
  98. Echocardiography evaluation of left ventricular diastolic function in elderly women with metabolic syndrome
  99. Tailored surgery in inguinal hernia repair. The role of subarachnoid anesthesia: a retrospective study
  100. The factors affecting early death in newly diagnosed APL patients
  101. Review Article
  102. Oncological outcomes and quality of life after rectal cancer surgery
  103. Research Article
  104. MiR-638 repressed vascular smooth muscle cell glycolysis by targeting LDHA
  105. microRNA-16 via Twist1 inhibits EMT induced by PM2.5 exposure in human hepatocellular carcinoma
  106. Analyzing the semantic space of the Hippocratic Oath
  107. Fournier’s gangrene and intravenous drug abuse: an unusual case report and review of the literature
  108. Evaluation of surgical site infection in mini-invasive urological surgery
  109. Dihydromyricetin attenuates inflammation through TLR4/NF-kappaB pathway
  110. Clinico-pathological features of colon cancer patients undergoing emergency surgery: a comparison between elderly and non-elderly patients
  111. Case Report
  112. Appendix bleeding with painless bloody diarrhea: A case report and literature review
  113. Research Article
  114. Protective effects of specneuzhenide on renal injury in rats with diabetic nephropathy
  115. PBF, a proto-oncogene in esophageal carcinoma
  116. Use of rituximab in NHL malt type pregnant in I° trimester for two times
  117. Cancer- and non-cancer related chronic pain: from the physiopathological basics to management
  118. Case report
  119. Non-surgical removal of dens invaginatus in maxillary lateral incisor using CBCT: Two-year follow-up case report
  120. Research Article
  121. Risk factors and drug resistance of the MDR Acinetobacter baumannii in pneumonia patients in ICU
  122. Accuracy of tumor perfusion assessment in Rat C6 gliomas model with USPIO
  123. Lemann Index for Assessment of Crohn’s Disease: Correlation with the Quality of Life, Endoscopic Disease activity, Magnetic Resonance Index of Activity and C- Reactive Protein
  124. Case report
  125. Münchausen syndrome as an unusual cause of pseudo-resistant hypertension: a case report
  126. Research Article
  127. Renal artery embolization before radical nephrectomy for complex renal tumour: which are the true advantages?
  128. Prognostic significance of CD276 in non-small cell lung cancer
  129. Potential drug-drug interactions in acute ischemic stroke patients at the Neurological Intensive Care Unit
  130. Effect of vitamin D3 on lung damage induced by cigarette smoke in mice
  131. CircRNA-UCK2 increased TET1 inhibits proliferation and invasion of prostate cancer cells via sponge miRNA-767-5p
  132. Case report
  133. Partial hydatidiform mole and coexistent live fetus: a case report and review of the literature
  134. Research Article
  135. Effect of NGR1 on the atopic dermatitis model and its mechanisms
  136. Clinical features of infertile men carrying a chromosome 9 translocation
  137. Review Article
  138. Expression and role of microRNA-663b in childhood acute lymphocytic leukemia and its mechanism
  139. Case Report
  140. Mature cystic teratoma of the pancreas: A rare cystic neoplasm
  141. Research Article
  142. Application of exercised-based pre-rehabilitation in perioperative period of patients with gastric cancer
  143. Case Report
  144. Predictive factors of intestinal necrosis in acute mesenteric ischemia
  145. Research Article
  146. Application of exercised-based pre-rehabilitation in perioperative period of patients with gastric cancer
  147. Effects of dexmedetomidine on the RhoA /ROCK/ Nox4 signaling pathway in renal fibrosis of diabetic rats
  148. MicroRNA-181a-5p regulates inflammatory response of macrophages in sepsis
  149. Intraventricular pressure in non-communicating hydrocephalus patients before endoscopic third ventriculostomy
  150. CyclinD1 is a new target gene of tumor suppressor miR-520e in breast cancer
  151. CHL1 and NrCAM are primarily expressed in low grade pediatric neuroblastoma
  152. Epidemiological characteristics of postoperative sepsis
  153. Association between unstable angina and CXCL17: a new potential biomarker
  154. Cardiac strains as a tool for optimization of cardiac resynchronization therapy in non-responders: a pilot study
  155. Case Report
  156. Resuscitation following a bupivacaine injection for a cervical paravertebral block
  157. Research Article
  158. CGF treatment of leg ulcers: A randomized controlled trial
  159. Surgical versus sequential hybrid treatment of carotid body tumors
https://doi.org/10.1515/med-2019-0108
Keywords for this article
CyclinD1; miR-520e; Breast cancer
Creative Commons
BY-NC-ND 4.0

Articles in the same Issue

  1. Research Article
  2. Prostate Cancer-Specific of DD3-driven oncolytic virus-harboring mK5 gene
  3. Case Report
  4. Pediatric acute paradoxical cerebral embolism with pulmonary embolism caused by extremely small patent foramen ovale
  5. Research Article
  6. Associations between ambient temperature and acute myocardial infarction
  7. Case Report
  8. Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
  9. Research Article
  10. METTL3 promotes the proliferation and mobility of gastric cancer cells
  11. The C677T polymorphism of the methylenetetrahydrofolate reductase gene and susceptibility to late-onset Alzheimer’s disease
  12. microRNA-1236-3p regulates DDP resistance in lung cancer cells
  13. Review Article
  14. The link between thyroid autoimmunity, depression and bipolar disorder
  15. Research Article
  16. Effects of miR-107 on the Chemo-drug sensitivity of breast cancer cells
  17. Analysis of pH dose-dependent growth of sulfate-reducing bacteria
  18. Review Article
  19. Musculoskeletal clinical and imaging manifestations in inflammatory bowel diseases
  20. Research Article
  21. Regional hyperthermia combined with chemotherapy in advanced gastric cancer
  22. Analysis of hormone receptor status in primary and recurrent breast cancer via data mining pathology reports
  23. Morphological and isokinetic strength differences: bilateral and ipsilateral variation by different sport activity
  24. The reliability of adjusting stepped care based on FeNO monitoring for patients with chronic persistent asthma
  25. Comparison of the clinical outcomes of two physiological ischemic training methods in patients with coronary heart disease
  26. Analysis of ticagrelor’s cardio-protective effects on patients with ST-segment elevation acute coronary syndrome accompanied with diabetes
  27. Computed tomography findings in patients with Samter’s Triad: an observational study
  28. Case Report
  29. A spinal subdural hematoma induced by guidewire-based lumbar drainage in a patient with ruptured intracranial aneurysms
  30. Research Article
  31. High expression B3GAT3 is related with poor prognosis of liver cancer
  32. Effects of light touch on balance in patients with stroke
  33. Oncoprotein LAMTOR5 activates GLUT1 via upregulating NF-κB in liver cancer
  34. Effects of budesonide combined with noninvasive ventilation on PCT, sTREM-1, chest lung compliance, humoral immune function and quality of life in patients with AECOPD complicated with type II respiratory failure
  35. Prognostic significance of lymph node ratio in ovarian cancer
  36. Case Report
  37. Brainstem anaesthesia after retrobulbar block
  38. Review Article
  39. Treating infertility: current affairs of cross-border reproductive care
  40. Research Article
  41. Serum inflammatory cytokines comparison in gastric cancer therapy
  42. Behavioural and psychological symptoms in neurocognitive disorders: Specific patterns in dementia subtypes
  43. MRI and bone scintigraphy for breast cancer bone metastase: a meta-analysis
  44. Comparative study of back propagation artificial neural networks and logistic regression model in predicting poor prognosis after acute ischemic stroke
  45. Analysis of the factors affecting the prognosis of glioma patients
  46. Compare fuhrman nuclear and chromophobe tumor grade on chromophobe RCC
  47. Case Report
  48. Signet ring B cell lymphoma: A potential diagnostic pitfall
  49. Research Article
  50. Subparaneural injection in popliteal sciatic nerve blocks evaluated by MRI
  51. Loneliness in the context of quality of life of nursing home residents
  52. Biological characteristics of cervical precancerous cell proliferation
  53. Effects of Rehabilitation in Bankart Lesion in Non-athletes: A report of three cases
  54. Management of complications of first instance of hepatic trauma in a liver surgery unit: Portal vein ligation as a conservative therapeutic strategy
  55. Matrix metalloproteinase 2 knockdown suppresses the proliferation of HepG2 and Huh7 cells and enhances the cisplatin effect
  56. Comparison of laparoscopy and open radical nephrectomy of renal cell cancer
  57. Case Report
  58. A severe complication of myocardial dysfunction post radiofrequency ablation treatment of huge hepatic hemangioma: a case report and literature review
  59. Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report
  60. Research Article
  61. Binge eating disorder and related features in bariatric surgery candidates
  62. Propofol versus 4-hydroxybutyric acid in pediatric cardiac catheterizations
  63. Nasointestinal tube in mechanical ventilation patients is more advantageous
  64. The change of endotracheal tube cuff pressure during laparoscopic surgery
  65. Correlation between iPTH levels on the first postoperative day after total thyroidectomy and permanent hypoparathyroidism: our experience
  66. Case Report
  67. Primary angiosarcoma of the kidney: case report and comprehensive literature review
  68. Research Article
  69. miR-107 enhances the sensitivity of breast cancer cells to paclitaxel
  70. Incidental findings in dental radiology are concerning for family doctors
  71. Suffering from cerebral small vessel disease with and without metabolic syndrome
  72. A meta-analysis of robot assisted laparoscopic radical prostatectomy versus laparoscopic radical prostatectomy
  73. Indications and outcomes of splenectomy for hematological disorders
  74. Expression of CENPE and its prognostic role in non-small cell lung cancer
  75. Barbed suture and gastrointestinal surgery. A retrospective analysis
  76. Using post transplant 1 week Tc-99m DTPA renal scan as another method for predicting renal graft failure
  77. The pseudogene PTTG3P promotes cell migration and invasion in esophageal squamous cell carcinoma
  78. Lymph node ratio versus TNM system as prognostic factor in colorectal cancer staging. A single Center experience
  79. Review Article
  80. Minimally invasive pilonidal sinus treatment: A narrative review
  81. Research Article
  82. Anatomical workspace study of Endonasal Endoscopic Transsphenoidal Approach
  83. Hounsfield Units on Lumbar Computed Tomography for Predicting Regional Bone Mineral Density
  84. Communication
  85. Aspirin, a potential GLUT1 inhibitor in a vascular endothelial cell line
  86. Research Article
  87. Osteopontin and fatty acid binding protein in ifosfamide-treated rats
  88. Familial polyposis coli: the management of desmoid tumor bleeding
  89. microRNA-27a-3p down-regulation inhibits malignant biological behaviors of ovarian cancer by targeting BTG1
  90. PYCR1 is associated with papillary renal cell carcinoma progression
  91. Prediction of recurrence-associated death from localized prostate cancer with a charlson comorbidity index–reinforced machine learning model
  92. Colorectal cancer in the elderly patient: the role of neo-adjuvant therapy
  93. Association between MTHFR genetic polymorphism and Parkinson’s disease susceptibility: a meta-analysis
  94. Metformin can alleviate the symptom of patient with diabetic nephropathy through reducing the serum level of Hcy and IL-33
  95. Case Report
  96. Severe craniofacial trauma after multiple pistol shots
  97. Research Article
  98. Echocardiography evaluation of left ventricular diastolic function in elderly women with metabolic syndrome
  99. Tailored surgery in inguinal hernia repair. The role of subarachnoid anesthesia: a retrospective study
  100. The factors affecting early death in newly diagnosed APL patients
  101. Review Article
  102. Oncological outcomes and quality of life after rectal cancer surgery
  103. Research Article
  104. MiR-638 repressed vascular smooth muscle cell glycolysis by targeting LDHA
  105. microRNA-16 via Twist1 inhibits EMT induced by PM2.5 exposure in human hepatocellular carcinoma
  106. Analyzing the semantic space of the Hippocratic Oath
  107. Fournier’s gangrene and intravenous drug abuse: an unusual case report and review of the literature
  108. Evaluation of surgical site infection in mini-invasive urological surgery
  109. Dihydromyricetin attenuates inflammation through TLR4/NF-kappaB pathway
  110. Clinico-pathological features of colon cancer patients undergoing emergency surgery: a comparison between elderly and non-elderly patients
  111. Case Report
  112. Appendix bleeding with painless bloody diarrhea: A case report and literature review
  113. Research Article
  114. Protective effects of specneuzhenide on renal injury in rats with diabetic nephropathy
  115. PBF, a proto-oncogene in esophageal carcinoma
  116. Use of rituximab in NHL malt type pregnant in I° trimester for two times
  117. Cancer- and non-cancer related chronic pain: from the physiopathological basics to management
  118. Case report
  119. Non-surgical removal of dens invaginatus in maxillary lateral incisor using CBCT: Two-year follow-up case report
  120. Research Article
  121. Risk factors and drug resistance of the MDR Acinetobacter baumannii in pneumonia patients in ICU
  122. Accuracy of tumor perfusion assessment in Rat C6 gliomas model with USPIO
  123. Lemann Index for Assessment of Crohn’s Disease: Correlation with the Quality of Life, Endoscopic Disease activity, Magnetic Resonance Index of Activity and C- Reactive Protein
  124. Case report
  125. Münchausen syndrome as an unusual cause of pseudo-resistant hypertension: a case report
  126. Research Article
  127. Renal artery embolization before radical nephrectomy for complex renal tumour: which are the true advantages?
  128. Prognostic significance of CD276 in non-small cell lung cancer
  129. Potential drug-drug interactions in acute ischemic stroke patients at the Neurological Intensive Care Unit
  130. Effect of vitamin D3 on lung damage induced by cigarette smoke in mice
  131. CircRNA-UCK2 increased TET1 inhibits proliferation and invasion of prostate cancer cells via sponge miRNA-767-5p
  132. Case report
  133. Partial hydatidiform mole and coexistent live fetus: a case report and review of the literature
  134. Research Article
  135. Effect of NGR1 on the atopic dermatitis model and its mechanisms
  136. Clinical features of infertile men carrying a chromosome 9 translocation
  137. Review Article
  138. Expression and role of microRNA-663b in childhood acute lymphocytic leukemia and its mechanism
  139. Case Report
  140. Mature cystic teratoma of the pancreas: A rare cystic neoplasm
  141. Research Article
  142. Application of exercised-based pre-rehabilitation in perioperative period of patients with gastric cancer
  143. Case Report
  144. Predictive factors of intestinal necrosis in acute mesenteric ischemia
  145. Research Article
  146. Application of exercised-based pre-rehabilitation in perioperative period of patients with gastric cancer
  147. Effects of dexmedetomidine on the RhoA /ROCK/ Nox4 signaling pathway in renal fibrosis of diabetic rats
  148. MicroRNA-181a-5p regulates inflammatory response of macrophages in sepsis
  149. Intraventricular pressure in non-communicating hydrocephalus patients before endoscopic third ventriculostomy
  150. CyclinD1 is a new target gene of tumor suppressor miR-520e in breast cancer
  151. CHL1 and NrCAM are primarily expressed in low grade pediatric neuroblastoma
  152. Epidemiological characteristics of postoperative sepsis
  153. Association between unstable angina and CXCL17: a new potential biomarker
  154. Cardiac strains as a tool for optimization of cardiac resynchronization therapy in non-responders: a pilot study
  155. Case Report
  156. Resuscitation following a bupivacaine injection for a cervical paravertebral block
  157. Research Article
  158. CGF treatment of leg ulcers: A randomized controlled trial
  159. Surgical versus sequential hybrid treatment of carotid body tumors
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 8.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/med-2019-0108/html
Scroll to top button